[
  {
    "ts": "2026-02-11T15:35:05+00:00",
    "headline": "Pfizer (PFE) Closes 2025 on Solid Note, Returns $9.8B to Shareholders",
    "summary": "Pfizer Inc. (NYSE:PFE) is included among the Dividend Champions, Contenders, and Challengers List: 15 Highest Yielding Stocks. Pfizer Inc. (NYSE:PFE) reported its Q4 2025 results on February 3. The company posted revenue of $17.56 billion, falling slightly by 1.1% from a year earlier. On the earnings call, Chairman and CEO Albert Bourla asserted that the […]",
    "url": "https://finance.yahoo.com/news/pfizer-pfe-closes-2025-solid-153505495.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "0cf1fc9f-0c9b-32ae-9c21-a535575d1f02",
      "content": {
        "id": "0cf1fc9f-0c9b-32ae-9c21-a535575d1f02",
        "contentType": "STORY",
        "title": "Pfizer (PFE) Closes 2025 on Solid Note, Returns $9.8B to Shareholders",
        "description": "",
        "summary": "Pfizer Inc. (NYSE:PFE) is included among the Dividend Champions, Contenders, and Challengers List: 15 Highest Yielding Stocks. Pfizer Inc. (NYSE:PFE) reported its Q4 2025 results on February 3. The company posted revenue of $17.56 billion, falling slightly by 1.1% from a year earlier. On the earnings call, Chairman and CEO Albert Bourla asserted that the […]",
        "pubDate": "2026-02-11T15:35:05Z",
        "displayTime": "2026-02-11T15:35:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Pfizer (PFE) Closes 2025 on Solid Note, Returns $9.8B to Shareholders",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UKiv8LHLxutAA7dDIzr_pw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1v0rnd.QZj0de1gLzaNuAg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-closes-2025-solid-153505495.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-closes-2025-solid-153505495.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T15:35:00+00:00",
    "headline": "Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip.",
    "summary": "Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks.",
    "url": "https://www.fool.com/investing/2026/02/11/healthcare-stock-sink-buy-dip-pfe-lly-nvo/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "f672f5cd-120a-3c48-b229-0fb9c3715316",
      "content": {
        "id": "f672f5cd-120a-3c48-b229-0fb9c3715316",
        "contentType": "STORY",
        "title": "Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip.",
        "description": "",
        "summary": "Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks.",
        "pubDate": "2026-02-11T15:35:00Z",
        "displayTime": "2026-02-11T15:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/44f260e24493a6c08c874d6a367d54b7",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "Weight loss drugs in a box.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HOakPIrPMZzDxJsu3ZTwFA--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/44f260e24493a6c08c874d6a367d54b7.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xNt10sy25xjDsXix7qMQcw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/44f260e24493a6c08c874d6a367d54b7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/11/healthcare-stock-sink-buy-dip-pfe-lly-nvo/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/healthcare-stocks-sinking-2-buy-153500199.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "INTC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T13:09:00+00:00",
    "headline": "Can Pfizer's New & Acquired Drugs Offset Its Looming Patent Cliff?",
    "summary": "PFE bets on new and acquired drugs to reignite growth as COVID sales fade and a 2026-2030 patent cliff threatens key blockbusters.",
    "url": "https://finance.yahoo.com/news/pfizers-acquired-drugs-offset-looming-130900387.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "ea2b5616-f63a-34ac-95ef-b1e424566e82",
      "content": {
        "id": "ea2b5616-f63a-34ac-95ef-b1e424566e82",
        "contentType": "STORY",
        "title": "Can Pfizer's New & Acquired Drugs Offset Its Looming Patent Cliff?",
        "description": "",
        "summary": "PFE bets on new and acquired drugs to reignite growth as COVID sales fade and a 2026-2030 patent cliff threatens key blockbusters.",
        "pubDate": "2026-02-11T13:09:00Z",
        "displayTime": "2026-02-11T13:09:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ffSS19YaoL36xXdlr0Ip4A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mJhhM1.2_VWzkATXxZYL_w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizers-acquired-drugs-offset-looming-130900387.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizers-acquired-drugs-offset-looming-130900387.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "AZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T13:01:00+00:00",
    "headline": "CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside",
    "summary": "CRMD heads into Q4 earnings with DefenCath driving revenues, boosted by strong outpatient dialysis use and added contributions from acquired Melinta products.",
    "url": "https://finance.yahoo.com/news/cormedix-banks-defencath-sales-q4-130100951.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "0a545c5c-1b76-39fe-8573-02c70f2bd6b4",
      "content": {
        "id": "0a545c5c-1b76-39fe-8573-02c70f2bd6b4",
        "contentType": "STORY",
        "title": "CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside",
        "description": "",
        "summary": "CRMD heads into Q4 earnings with DefenCath driving revenues, boosted by strong outpatient dialysis use and added contributions from acquired Melinta products.",
        "pubDate": "2026-02-11T13:01:00Z",
        "displayTime": "2026-02-11T13:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/4f278dd92e23382650f269f90b5fb0c9",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/F2U5YD8Wk7dT2wbWDBGXZg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4f278dd92e23382650f269f90b5fb0c9.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/565G_.yU2UMQcw4nHig1TQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4f278dd92e23382650f269f90b5fb0c9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cormedix-banks-defencath-sales-q4-130100951.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cormedix-banks-defencath-sales-q4-130100951.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRMD"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]